Clinical Trials Logo

Cerebral Cavernous Malformation clinical trials

View clinical trials related to Cerebral Cavernous Malformation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05085561 Active, not recruiting - Clinical trials for Cerebral Cavernous Malformation

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

SYCAMORE
Start date: March 17, 2022
Phase: Phase 2
Study type: Interventional

This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in subjects with symptomatic cerebral cavernous malformation (CCM).

NCT ID: NCT02946866 Active, not recruiting - Clinical trials for Intracerebral Hemorrhage

CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study

CHOCOOATE
Start date: June 2016
Phase:
Study type: Observational

The aim of this prospective study is to reveal the natural history of symptomatic hemorrhage in adult patients with cerebral cavernous malformation with the goal of informing the treatment plan.

NCT ID: NCT02603328 Active, not recruiting - Clinical trials for Cerebral Cavernous Malformation

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

AT CASH EPOC
Start date: July 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by validated quantitative susceptibility mapping (QSM) MRI studies in patients who suffered a symptomatic bleed within the preceding one year.